Clinical trial
Efficacy (Induction of Response/Remission) and Safety Study in Patients With…
NCT00295165 · Genzyme, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00295165 |
|---|---|
| Title | Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease |
| Official title | Randomized, Double-Blind, Placebo-Controlled, Phase 3 Induction Study to Assess the Efficacy and Safety of 6µg Sargramostim (Leukine) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn Disease |
| Intervention type | Drug |
| Interventions | Sargramostim (Leukine), Placebo |
| Enrollment | 33 |
| Start date | Jan 1, 2006 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Feb 23, 2006 |
| Last update posted | Dec 4, 2013 |
| Countries | Australia, Brazil, Bulgaria, Canada, Israel, New Zealand, Romania, Russia, South Africa, Ukraine, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: